Screener
Nektar Therapeutics NKTR Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at March 31, 2026 or December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 390,000,000 shares authorized; 29,472,092 shares and 20,378,832 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 2 |
| Capital in excess of par value | 4,382,437 | 3,850,099 |
| Accumulated other comprehensive income (loss) | (1,034) | 17 |
| Accumulated deficit | (3,805,190) | (3,760,286) |
| Total stockholders’ equity | 576,216 | 89,832 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's common stock?
- Nektar Therapeutics (NKTR) reported common stock of 390M in Q1 2026.
- How has Nektar Therapeutics's common stock changed year-over-year?
- Nektar Therapeutics's common stock increased by 30.0% year-over-year, from 300M to 390M.
- What is the long-term trend for Nektar Therapeutics's common stock?
- Over 5 years (2020 to 2025), Nektar Therapeutics's common stock has grown at a 636.5% compound annual growth rate (CAGR), from 18K to 390M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Nektar Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude